Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Erasca (ERAS) Other Non Operating Income (2023 - 2026)

Erasca posted quarterly Other Non Operating Income of $22000.0 for Q1 2026, up 128.95% year-on-year from $9609.2 in Q1 2025, and up 159.46% on a QoQ basis from -$37000.0 in Q3 2025.

Erasca (ERAS) has 4 years of Other Non Operating Income data on file, last reported at $22000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Other Non Operating Income rose 128.95% year-over-year to $22000.0; the trailing twelve-month figure through Mar 2026 stood at $82000.0 (changed N/A YoY), and the FY2022 full-year result was -$257000.0, down 181.85% from the prior year.
  • Other Non Operating Income for Q1 2026 stood at $22000.0, up from -$37000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $173000.0 in Q3 2024 and bottomed at -$76000.0 in Q1 2025.
  • The 4-year median for Other Non Operating Income is -$37000.0 (2025), against an average of $6600.0.
  • The widest annual swing landed in 2024, when Other Non Operating Income jumped 453.06%; it then slumped 121.39% in 2025.
  • A 4-year view of Other Non Operating Income shows it stood at -$49000.0 in 2023, then surged by 453.06% to $173000.0 in 2024, then plunged by 121.39% to -$37000.0 in 2025, then soared by 159.46% to $22000.0 in 2026.
  • The last three Other Non Operating Income figures came in at $22000.0 (Q1 2026), -$37000.0 (Q3 2025), and -$76000.0 (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Erasca 4.21 Bn 3.97 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 22,000.00
Sep 30, 2025 -37,000.00
Mar 31, 2025 -76,000.00
Sep 30, 2024 173,000.00
Sep 30, 2023 -49,000.00